Jung Young Kul
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Korea.
Korean J Gastroenterol. 2016 Mar;67(3):132-6. doi: 10.4166/kjg.2016.67.3.132.
Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have been studied and published. With all oral DAA therapy showing sustained virological response rate of 80-90% with minimal adverse events, HCV eradication has now become a realistic goal. DAA combination treatments were approved and adapted to practice in Korea in 2015, and Korean Association for the Study of the Liver (KASL) has revised the guideline based on the systematic approach that reflects evidence-based medicine and expert opinions. In this article, new recommendations for treatment of chronic HCV genotype 2 and 3 infected patients will be introduced base on KASL practice guidelines for management of hepatitis C that has been updated in 2015.
自从直接抗病毒药物（DAA）获批并投放市场以来，关于不含干扰素的DAA联合疗法的疗效、不良反应及药物相互作用的众多研究已被开展并发表。所有口服DAA疗法的持续病毒学应答率达80 - 90%，且不良事件极少，丙型肝炎病毒（HCV）根除如今已成为一个现实目标。DAA联合治疗于2015年在韩国获批并应用于临床实践，韩国肝脏研究协会（KASL）基于反映循证医学和专家意见的系统方法修订了指南。本文将基于2015年更新的KASL丙型肝炎管理实践指南，介绍针对慢性HCV基因2型和3型感染患者的新治疗建议。
